BMY

#128
Bristol-Myers Squibb Company Common Stock
57.1 8 USD
+0.62%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
56.82
57.26
Jahresspanne
42.52
62.89
Tagesänderung
+0.62%
Monatliche Änderung
-0.92%
6 month change
+15.94%
Jahresänderung
+19.50%
Vorheriger Schlusskurs
56.8 3
Open
56.9 0
Tief
56.8 2
High
57.2 6
Volumen
7 641
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
  • Market Capitalization 116.77 B
  • Employee 33 K
  • Founded N/A
  • CEO Chris Boerner
  • Website www.bms.com
  • Headquarter Delaware, United States
  • FIGI BBG000DQLV23
  • Industry Arzneimittelhersteller – allgemein
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
16.99
Preis-Umsatz-Verhältnis
2.55
Dividende je Aktie
0.63
Dividendenrendite in %
7.19

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.

Nachrichten